| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ENGN | Common Shares | Award | $6.45M | +645K | +184.97% | $10.00 | 994K | Feb 20, 2024 | Held by Lumira Ventures IV, L.P. | F1, F2, F5 |
| transaction | ENGN | Common Shares | Award | $1.55M | +155K | +184.97% | $10.00 | 239K | Feb 20, 2024 | Held by Lumira Ventures IV (International), L.P. | F1, F2, F5 |
| holding | ENGN | Common Shares | 1.34M | Feb 20, 2024 | Held by Lumira Ventures III, L.P. | F1, F3, F5 | |||||
| holding | ENGN | Common Shares | 44.6K | Feb 20, 2024 | Held by Lumira Ventures III (International), L.P. | F1, F3, F5 | |||||
| holding | ENGN | Common Shares | 1.08M | Feb 20, 2024 | Held by Merck Lumira Biosciences Fund, L.P. | F1, F4, F5 | |||||
| holding | ENGN | Common Shares | 153K | Feb 20, 2024 | Held by Merck Lumira Biosciences Fund (Quebec), L.P. | F1, F4, F5 |
Lumira Capital Investment Management Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | This Form 4 is filed jointly by Lumira Ventures III, L.P. ("Lumira III"), Lumira Ventures III (International), L.P. ("Lumira III Int'l"), Lumira Ventures IV, L.P. ("Lumira IV"), Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"), Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"), Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"), Lumira Capital Investment Management Inc. ("Lumira Mgmt"), Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc. and Lumira GP Holdings Co. (collectively, the "Reporting Person"). |
| F2 | Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt. |
| F3 | Lumira III and Lumira III Int'l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Mgmt. Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. |
| F4 | Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co. |
| F5 | Gerald Brunk, a director of the Issuer, is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt and reports his beneficial ownership of these securities on a separate Form 4. Each of Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any. |
Mr. Brunk serves on the Issuer's Board of Directors (the "Board") as a representative of the Reporting Person. By virtue of his representation on the Board, for purposes of Section 16 of the Exchange Act, the Reporting Person may be deemed to be a director of the Issuer by deputization of Mr. Brunk.